MedTrace Logo

Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse

NCT05480046 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 275

Last updated 2025-12-05

No results posted yet for this study

Summary

This is a prospective, non-interventional, multicentre study designed to collect information about the effectiveness, safety and tolerability of Risperidone ISM in patients diagnosed with schizophrenia who are suffering an acute exacerbation, according to routine clinical practice.

Conditions

Interventions

DRUG

Risperidone ISM

Risperidone ISM is administered every 4 weeks

Sponsors & Collaborators

  • Rovi Pharmaceuticals Laboratories

    lead INDUSTRY

Principal Investigators

  • Christoph U Correll · Charite University, Berlin, Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-18
Primary Completion
2025-03-13
Completion
2025-03-13

Countries

  • Germany
  • Italy
  • Portugal
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05480046 on ClinicalTrials.gov